In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter
- PMID: 8568807
- DOI: 10.1021/jm950117b
In vitro and in vivo studies of benzisoquinoline ligands for the brain synaptic vesicle monoamine transporter
Abstract
Tetrabenazine is a high-affinity inhibitor of the vesicular monoamine transporter in mammalian brain. As part of a program to develop in vivo imaging agents for these transporters in human brain, a series of 2-alkylated dihydrotetrabenazine ligands was synthesized and evaluated in vitro and in vivo for binding to the brain vesicular monoamine transporter. Additions of organometallic reagents to tetrabenazine produced 2-methyl, 2-ethyl, 2-n-propyl, 2-isopropyl, and 2-isobutyl derivatives of dihydrotetrabenazine. The stereochemistry and conformation of the addition products were thoroughly verified by two-dimensional NMR techniques. All of these alkyl derivatives displayed in vitro affinity for the vesicular monoamine transporter binding site in rat brain using competitive assays with the radioligand [3H]methoxytetrabenazine. Except for the isopropyl derivative, all compounds when tested at 10 mg/kg iv showed an ability to inhibit in vivo accumulation of the radioligand [11C]methoxytetrabenazine in the mouse brain striatum. Derivatives with small alkyl groups (methyl, ethyl) were more effective than those with large groups (propyl, isobutyl). These studies suggest that large groups in the 2-position of the benzisoquinoline structure will significantly diminish both in vitro and in vivo binding of these compounds to the vesicular monoamine transporter.
Similar articles
-
In vivo measures of dopaminergic radioligands in the rat brain: equilibrium infusion studies.Synapse. 2002 Mar 1;43(3):188-94. doi: 10.1002/syn.10039. Synapse. 2002. PMID: 11793424
-
Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.Synapse. 2000 Mar 15;35(4):250-5. doi: 10.1002/(SICI)1098-2396(20000315)35:4<250::AID-SYN2>3.0.CO;2-S. Synapse. 2000. PMID: 10657034
-
Differential effects of scopolamine on in vivo binding of dopamine transporter and vesicular monoamine transporter radioligands in rat brain.Exp Neurol. 2004 Aug;188(2):387-90. doi: 10.1016/j.expneurol.2004.05.001. Exp Neurol. 2004. PMID: 15246838
-
In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter.FASEB J. 2000 Dec;14(15):2401-13. doi: 10.1096/fj.00-0204rev. FASEB J. 2000. PMID: 11099458 Review.
-
Transport mechanisms in acetylcholine and monoamine storage.FASEB J. 2000 Dec;14(15):2423-34. doi: 10.1096/fj.00-0203rev. FASEB J. 2000. PMID: 11099460 Review.
Cited by
-
Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.Bioorg Med Chem Lett. 2005 Oct 15;15(20):4463-6. doi: 10.1016/j.bmcl.2005.07.032. Bioorg Med Chem Lett. 2005. PMID: 16112864 Free PMC article.
-
Lobelane analogues as novel ligands for the vesicular monoamine transporter-2.Bioorg Med Chem. 2005 Jun 2;13(12):3899-909. doi: 10.1016/j.bmc.2005.04.013. Bioorg Med Chem. 2005. PMID: 15911306 Free PMC article.
-
Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.Bioorg Med Chem. 2010 Jan 15;18(2):640-9. doi: 10.1016/j.bmc.2009.12.002. Epub 2009 Dec 6. Bioorg Med Chem. 2010. PMID: 20036131 Free PMC article.
-
Vesicular monoamine transporter 2: role as a novel target for drug development.AAPS J. 2006 Nov 10;8(4):E682-92. doi: 10.1208/aapsj080478. AAPS J. 2006. PMID: 17233532 Free PMC article. Review.
-
Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.J Med Chem. 2005 Aug 25;48(17):5551-60. doi: 10.1021/jm0501228. J Med Chem. 2005. PMID: 16107155 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials